TY - JOUR
T1 - Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24
AU - Gudmundsson, Julius
AU - Sulem, Patrick
AU - Manolescu, Andrei
AU - Amundadottir, Laufey T.
AU - Gudbjartsson, Daniel
AU - Helgason, Agnar
AU - Rafnar, Thorunn
AU - Bergthorsson, Jon T.
AU - Agnarsson, Bjarni A.
AU - Baker, Adam
AU - Sigurdsson, Asgeir
AU - Benediktsdottir, Kristrun R.
AU - Jakobsdottir, Margret
AU - Xu, Jianfeng
AU - Blondal, Thorarinn
AU - Kostic, Jelena
AU - Sun, Jielin
AU - Ghosh, Shyamali
AU - Stacey, Simon N.
AU - Mouy, Magali
AU - Saemundsdottir, Jona
AU - Backman, Valgerdur M.
AU - Kristjansson, Kristleifur
AU - Tres, Alejandro
AU - Partin, Alan W.
AU - Albers-Akkers, Marjo T.
AU - Godino-Ivan Marcos, Javier
AU - Walsh, Patrick C.
AU - Swinkels, Dorine W.
AU - Navarrete, Sebastian
AU - Isaacs, Sarah D.
AU - Aben, Katja K.
AU - Graif, Theresa
AU - Cashy, John
AU - Ruiz-Echarri, Manuel
AU - Wiley, Kathleen E.
AU - Suarez, Brian K.
AU - Witjes, J. Alfred
AU - Frigge, Mike
AU - Ober, Carole
AU - Jonsson, Eirikur
AU - Einarsson, Gudmundur V.
AU - Mayordomo, Jose I.
AU - Kiemeney, Lambertus A.
AU - Isaacs, William B.
AU - Catalona, William J.
AU - Barkardottir, Rosa B.
AU - Gulcher, Jeffrey R.
AU - Thorsteinsdottir, Unnur
AU - Kong, Augustine
AU - Stefansson, Kari
N1 - Funding Information:
We thank the patients and their family members whose contributions made this work possible. We also thank the nurses at Noatun (deCODE’s sample recruitment center), personnel at the deCODE core facilities and at the Department of Pathology at Landspitali University Hospital for their hard work and enthusiasm. We acknowledge M. Gielzak, G. Yan and J. Sauvageot (Johns Hopkins Hospital) for their assistance and W.T. Gerrard, M. Duhon, John and Jennifer Chalsty and D. Koch (also at Johns Hopkins Hospital) for their support. We also thank participants and clinicians at the Northwestern University, the University of Chicago, Johns Hopkins Hospital, the Radboud University Nijmegen Medical Centre and the Oncology Department of the Zaragoza Hospital. This project was funded in part by contract number 018827 (Polygene) from the 6th Framework Program of the European Union and by Department of Defense Congressionally Directed Medical Research Program grant W81XWH-05-1-0074.
PY - 2007/5
Y1 - 2007/5
N2 - Prostate cancer is the most prevalent noncutaneous cancer in males in developed regions, with African American men having among the highest worldwide incidence and mortality rates. Here we report a second genetic variant in the 8q24 region that, in conjunction with another variant we recently discovered, accounts for about 11%-13% of prostate cancer cases in individuals of European descent and 31% of cases in African Americans. We made the current discovery through a genome-wide association scan of 1,453 affected Icelandic individuals and 3,064 controls using the Illumina HumanHap300 BeadChip followed by four replication studies. A key step in the discovery was the construction of a 14-SNP haplotype that efficiently tags a relatively uncommon (2%-4%) susceptibility variant in individuals of European descent that happens to be very common (∼42%) in African Americans. The newly identified variant shows a stronger association with affected individuals who have an earlier age at diagnosis.
AB - Prostate cancer is the most prevalent noncutaneous cancer in males in developed regions, with African American men having among the highest worldwide incidence and mortality rates. Here we report a second genetic variant in the 8q24 region that, in conjunction with another variant we recently discovered, accounts for about 11%-13% of prostate cancer cases in individuals of European descent and 31% of cases in African Americans. We made the current discovery through a genome-wide association scan of 1,453 affected Icelandic individuals and 3,064 controls using the Illumina HumanHap300 BeadChip followed by four replication studies. A key step in the discovery was the construction of a 14-SNP haplotype that efficiently tags a relatively uncommon (2%-4%) susceptibility variant in individuals of European descent that happens to be very common (∼42%) in African Americans. The newly identified variant shows a stronger association with affected individuals who have an earlier age at diagnosis.
UR - http://www.scopus.com/inward/record.url?scp=34247563453&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247563453&partnerID=8YFLogxK
U2 - 10.1038/ng1999
DO - 10.1038/ng1999
M3 - Article
C2 - 17401366
AN - SCOPUS:34247563453
SN - 1061-4036
VL - 39
SP - 631
EP - 637
JO - Nature Genetics
JF - Nature Genetics
IS - 5
ER -